company is funded until mid 2017, phase 3 patient enrollment has started, very reputable university is conducting and leading the trials, FDA granted fast track status, the product is already approved in over 50 countries world wide, everything is on track, market capitalization is around 100 Million USD, for a phase 3 company this might be on the lower end.
What is wrong?! - this simply does not add up as the stock price is loosing ground spiritless almost every session since the name change a few weeks ago and since the announcement of phase 3 start. Trust in management must be next to zero and trust in their ability to make this happen, almost inexistent. Many well paid board members and overpaid management people who do not seems to do much at all (there are just filings after filings, which btw can be easily outsourced at much lower cost), does not make investors feeling confident about this. I wonder what all those people are doing on a daily basis, it might be advisable that they at least visit a basic course in communication, as the jokers who present and speak for the company seem to be emotionless and it is more interesting watching paint dry than listen to them. The stock price movement most likely reflects investors feeling towards the management but then again how on earth could they convince investors to put 60 Million into this operation? They must obviously know more than joe public does, as said, it simply does not add up…..
